Skip to main content
. Author manuscript; available in PMC: 2009 Sep 22.
Published in final edited form as: Mol Cancer Ther. 2008 Nov;7(11):3575–3585. doi: 10.1158/1535-7163.MCT-08-0640

Figure 4. TMZ induces cell cycle checkpoint arrest and upregulates death receptors on glioma cells.

Figure 4

(A-F) Summary data of Gli36-EGFRvIII (A-C) and U251 (D-F) human glioma cells treated with TMZ (100 μM) for 24 (B,E), 72 h (C,F), or left untreated (A,D). Cells were pulsed for 1 h with bromodeoxyuridine, collected, stained, and cell cycle progression was analyzed by FACS. Data is expressed as percentage of cells in subG1, G1, S, or G2/M (G-I) Representative scatter plots of untreated Gli36 cells (G) and cells treated for 24 (H) or 72 h (I) with TMZ. (J) Western blot analysis demonstrating the effects of TMZ on the levels of total Chk1 and phosphorylated (p)Chk1. (K) Western blot analysis showing the expression of death receptor DR4 in U251 cells treated with TMZ for 24 or 72 h. All data is normalized to control cells (untreated). *p<0.05 vs. untreated cells.